Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
New Active Ingredient + Innovative Drug Delivery System = Business Success More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Generic Lansoprazole with international contrasted license and export experience. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
p38 MAP Kinase inhibitors as modulators of pro-inflammatory cytokine-expression for treatment of inflammation-related diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, or acute coronary syndrome. More
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
Anti-inflammatory drugs covalently linked to non-antibiotic macrolides. More
MIC-31 is a botanically derived potential drug candidate for gastric ulcer prevention and therapy. More
L-histidine is being developed as a prescription drug and as a dietary supplement for 1) chronic inflammatory gastrointestinal diseases; 2) conjunctivitis and seasonal allergic rhinitis; 3) infectious and non-infectious diarrheas; and 4) as an antioxidant More
Your selection
Browse By
- Therapeutic target
- Appendicitis
- Cholangitis, sclerosing
- Colitis
- Colitis, ulcerative
- Constipation
- Crohn's disease
- Diarrhea
- Dyspepsia
- Electrolyte replacement
- Emesis
- Emesis, motion
- Esophagitis
- Flatulence
- Food poisoning
- Gastritis
- Gastroesophageal reflux disorder
- Gastrointestinal (other)
- Gastrointestinal secretions
- Gastroprokinetic
- Helicobacter pylori
- Inflammatory bowel disease
- Irritable bowel syndrome
- Nausea
- Pancreatitis
- Ulcer
- Ulcer, gastric
- Ulcer, gastroduodenal
- Ulcer, peptic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us